Abstract
Targeted therapies affecting specific molecular target, expressed preferentially by neoplastic cells, block cancer growth. Current targets are represented by cell-surface trans-membrane proteins, intracellular proteins, and by growth factors. Today a targeted therapy exists for most commonly diagnosed types of human cancer often combined with chemotherapy or sometimes as monotherapy option. The epidermal growth factor receptors (EGFR) and vascular endothelial growth factors (VEGF) are known as the two main control key intracellular pathways, governing fundamental processes in cancer cells. The concept of using anti-EGFR and anti-VEGF strategies, as cancer treatment, has been recently developed and exploited extensively. We review targeted drugs currently available for routine treatment of lung, breast, colorectal and renal cell cancers, summarizing the history of identification and molecular characterization of targets or signaling pathways responsible for abnormal cell growth. We also focus on new targeted strategies, still under investigation, able to affect simultaneously tightly interconnected biological pathways or directed against new molecular targets.
Keywords: Target therapy, breast cancer, lung cancer, colorectal cancer, kidney cancer
Current Cancer Drug Targets
Title: Past, Present and Future of Targeted Therapy in Solid Tumors
Volume: 10 Issue: 5
Author(s): A. Palazzo, R. Iacovelli and E. Cortesi
Affiliation:
Keywords: Target therapy, breast cancer, lung cancer, colorectal cancer, kidney cancer
Abstract: Targeted therapies affecting specific molecular target, expressed preferentially by neoplastic cells, block cancer growth. Current targets are represented by cell-surface trans-membrane proteins, intracellular proteins, and by growth factors. Today a targeted therapy exists for most commonly diagnosed types of human cancer often combined with chemotherapy or sometimes as monotherapy option. The epidermal growth factor receptors (EGFR) and vascular endothelial growth factors (VEGF) are known as the two main control key intracellular pathways, governing fundamental processes in cancer cells. The concept of using anti-EGFR and anti-VEGF strategies, as cancer treatment, has been recently developed and exploited extensively. We review targeted drugs currently available for routine treatment of lung, breast, colorectal and renal cell cancers, summarizing the history of identification and molecular characterization of targets or signaling pathways responsible for abnormal cell growth. We also focus on new targeted strategies, still under investigation, able to affect simultaneously tightly interconnected biological pathways or directed against new molecular targets.
Export Options
About this article
Cite this article as:
Palazzo A., Iacovelli R. and Cortesi E., Past, Present and Future of Targeted Therapy in Solid Tumors, Current Cancer Drug Targets 2010; 10 (5) . https://dx.doi.org/10.2174/156800910791517145
DOI https://dx.doi.org/10.2174/156800910791517145 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Development and Characterization of Spray Dried Microparticles for Pulmonary Delivery of Antifungal Drug
Current Drug Delivery Polymorphisms in TOLL-Like Receptor Genes and their Roles in Allergic Asthma and Atopy
Recent Patents on Inflammation & Allergy Drug Discovery Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Current Medicinal Chemistry Silver Nanomaterials in Contemporary Molecular Physiology Research
Current Medicinal Chemistry Two Identical Twin Nitrogen Mustard Agents that Express Rapid Alkylation Activity at Physiological pH 7.4 and 37°C
Letters in Drug Design & Discovery High Throughput and Global Approaches to Gene Expression
Combinatorial Chemistry & High Throughput Screening Sequence and Structural Elements in the Mechanism of Function of Rhodopsin-Like Family of G Protein-Coupled-Receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Biomarkers for Early Detection of Liver Cancer: Focus on Clinical Evaluation
Protein & Peptide Letters Oncorine, the World First Oncolytic Virus Medicine and its Update in China
Current Cancer Drug Targets Mechanisms of Angiogenesis: Perspectives from Antiangiogenic Tumor Therapies
Current Angiogenesis (Discontinued) Podophyllotoxin: Current Perspectives
Current Bioactive Compounds In Vitro and In Vivo Performance of Novel Spray Dried Andrographolide Loaded Scleroglucan Based Formulation for Dry Powder Inhaler
Current Drug Delivery Tocilizumab Labeling with 99mTechnetium via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma
Anti-Cancer Agents in Medicinal Chemistry On the Nature of the Tumor-Initiating Cell
Current Stem Cell Research & Therapy Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry The Application of Stable Isotope Assisted Metabolomics in Biomedicine
Current Biotechnology Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Steroidal Conjugates and Their Pharmacological Applications
Current Medicinal Chemistry Pomegranate, its Components, and Modern Deliverable Formulations as Potential Botanicals in the Prevention and Treatment of Various Cancers
Current Drug Delivery